{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:26:28Z","timestamp":1793413588361,"version":"4.5.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:sec id=\"ab-noi230085-4\"><jats:title>IMPORTANCE<\/jats:title><jats:p>Nonmotor symptoms of Parkinson disease (PD) often predate the movement disorder by decades. Currently, there is no blood biomarker to define this prodromal phase.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi230085-5\"><jats:title>OBJECTIVE<\/jats:title><jats:p>To investigate whether \u03b1-synuclein in neuronally derived serum-extracellular vesicles identifies individuals at risk of developing PD and related dementia.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi230085-6\"><jats:title>DESIGN, SETTING, and PARTICIPANTS<\/jats:title><jats:p>This retrospective, cross-sectional multicenter study of serum samples included the Oxford Discovery, Marburg, Cologne, and Parkinson\u2019s Progression Markers Initiative cohorts. Participants were recruited from July 2013 through August 2023 and samples were analyzed from April 2022 through September 2023. The derivation group (n\u2009=\u2009170) included participants with isolated rapid eye movement sleep behavior disorder (iRBD) and controls. Two validation groups were used: the first (n\u2009=\u2009122) included participants with iRBD and controls and the second (n\u2009=\u2009263) included nonmanifest <jats:italic>GBA1<jats:sup>N409S<\/jats:sup><\/jats:italic> gene carriers, participants with iRBD or hyposmia, and available dopamine transporter single-photon emission computed tomography, healthy controls, and patients with sporadic PD. Overall the study included 199 participants with iRBD, 20 hyposmic participants with available dopamine transporter single-photon emission computed tomography, 146 nonmanifest <jats:italic>GBA1<jats:sup>N409S<\/jats:sup><\/jats:italic> gene carriers, 21 <jats:italic>GBA1<jats:sup>N409S<\/jats:sup><\/jats:italic> gene carrier patients with PD, 50 patients with sporadic PD, and 140 healthy controls. In the derivation group and validation group 1, participants with polysomnographically confirmed iRBD were included. In the validation group 2, at-risk participants with available Movement Disorder Society prodromal markers and serum samples were included. Among 580 potential participants, 4 were excluded due to alternative diagnoses.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi230085-7\"><jats:title>EXPOSURES<\/jats:title><jats:p>Clinical assessments, imaging, and serum collection.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi230085-8\"><jats:title>MAIN OUTCOME AND MEASURES<\/jats:title><jats:p>L1CAM-positive extracellular vesicles (L1EV) were immunocaptured from serum. \u03b1-Synuclein and syntenin-1 were measured by electrochemiluminescence. Area under the receiver operating characteristic (ROC) curve (AUC) with 95% CIs evaluated biomarker performance. Probable prodromal PD was determined using the updated Movement Disorder Society research criteria. Multiple linear regression models assessed the association between L1EV \u03b1-synuclein and prodromal markers.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi230085-9\"><jats:title>RESULTS<\/jats:title><jats:p>Among 576 participants included, the mean (SD) age was 64.30 (8.27) years, 394 were male (68.4%), and 182 were female (31.6%). A derived threshold of serum L1EV \u03b1-synuclein distinguished participants with iRBD from controls (AUC\u2009=\u20090.91; 95% CI, 0.86-0.96) and those with more than 80% probability of having prodromal PD from participants with less than 5% probability (AUC\u2009=\u20090.80; 95% CI, 0.71-0.89). Subgroup analyses revealed that specific combinations of prodromal markers were associated with increased L1EV \u03b1-synuclein levels. Across all cohorts, L1EV \u03b1-synuclein differentiated participants with more than 80% probability of having prodromal PD from current and historic healthy control populations (AUC\u2009=\u20090.90; 95% CI, 0.87-0.93), irrespective of initial diagnosis. L1EV \u03b1-synuclein was increased in at-risk participants with a positive cerebrospinal fluid seed amplification assay and was above the identified threshold in 80% of cases (n\u2009=\u200940) that phenoconverted to PD or related dementia.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi230085-10\"><jats:title>CONCLUSIONS AND RELEVANCE<\/jats:title><jats:p>L1EV \u03b1-synuclein in combination with prodromal markers should be considered in the stratification of those at high risk of developing PD and related Lewy body diseases.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.4398","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T16:01:17Z","timestamp":1701705677000},"page":"59","source":"Crossref","is-referenced-by-count":137,"title":["Neuronally Derived Extracellular Vesicle \u03b1-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease"],"prefix":"10.1001","volume":"81","author":[{"given":"Shijun","family":"Yan","sequence":"first","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"},{"name":"Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"},{"name":"Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Janzen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Philipps-University Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Barber","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"},{"name":"Oxford Parkinson\u2019s Disease Centre, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Seger","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Cologne, Faculty of Medicine, University of Cologne, K\u00f6ln, Germany"},{"name":"Institute of Neuroscience and Medicine (INM-3), Forschungszentrum J\u00fclich, J\u00fclich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sommerauer","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Cologne, Faculty of Medicine, University of Cologne, K\u00f6ln, Germany"},{"name":"Institute of Neuroscience and Medicine (INM-3), Forschungszentrum J\u00fclich, J\u00fclich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Marek","sequence":"additional","affiliation":[{"name":"Institute for Neurodegenerative Disorders, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele T.","family":"Hu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"},{"name":"Oxford Parkinson\u2019s Disease Centre, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Oertel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Philipps-University Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Tofaris","sequence":"additional","affiliation":[{"name":"Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom"},{"name":"Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"noi230085r1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.v34.10","article-title":"Update of the MDS research criteria for prodromal Parkinson\u2019s disease.","volume":"34","author":"Heinzel","year":"2019","journal-title":"Mov Disord"},{"issue":"3","key":"noi230085r2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/brain\/awz030","article-title":"Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.","volume":"142","author":"Postuma","year":"2019","journal-title":"Brain"},{"issue":"17","key":"noi230085r3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease.","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"noi230085r4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s40820-021-00753-w","article-title":"Multiplexed profiling of extracellular vesicles for biomarker development.","volume":"14","author":"Jiang","year":"2021","journal-title":"Nanomicro Lett"},{"key":"noi230085r5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad169","article-title":"Methodological considerations in neuronal extracellular vesicle isolation for a-synuclein biomarkers.","author":"Yan","year":"2023","journal-title":"Brain"},{"issue":"3","key":"noi230085r6","doi-asserted-by":"publisher","DOI":"10.1002\/jex2.v1.3","article-title":"L1CAM-associated extracellular vesicles: a systematic review of nomenclature, sources, separation, and characterization.","volume":"1","author":"Gomes","year":"2022","journal-title":"J Extracell Biol"},{"issue":"7","key":"noi230085r7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","article-title":"Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism.","volume":"91","author":"Jiang","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"noi230085r8","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/mds.v36.11","article-title":"Validation of a-synuclein in L1CAM-immunocaptured exosomes as a biomarker for the stratification of parkinsonian syndromes.","volume":"36","author":"Jiang","year":"2021","journal-title":"Mov Disord"},{"issue":"5","key":"noi230085r9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal a-synuclein is likely CNS-derived and increased in Parkinson\u2019s disease.","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"6","key":"noi230085r10","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/ene.v27.6","article-title":"A longitudinal study on a-synuclein in plasma neuronal exosomes as a biomarker for Parkinson\u2019s disease development and progression.","volume":"27","author":"Niu","year":"2020","journal-title":"Eur J Neurol"},{"issue":"3","key":"noi230085r11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00401-021-02324-0","article-title":"a-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson\u2019s disease from multiple system atrophy.","volume":"142","author":"Dutta","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"12","key":"noi230085r12","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1111\/ene.v29.12","article-title":"Different patterns of exosomal a-synuclein between Parkinson\u2019s disease and probable rapid eye movement sleep behavior disorder.","volume":"29","author":"Yan","year":"2022","journal-title":"Eur J Neurol"},{"issue":"12","key":"noi230085r13","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1002\/mds.v36.12","article-title":"Longitudinal changes in Parkinson\u2019s disease symptoms with and without rapid eye movement sleep behavior disorder: the Oxford Discovery Cohort Study.","volume":"36","author":"Liu","year":"2021","journal-title":"Mov Disord"},{"issue":"8","key":"noi230085r14","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsx071","article-title":"Prodromal Parkinsonism and neurodegenerative risk stratification in REM sleep behavior disorder.","volume":"40","author":"Barber","year":"2017","journal-title":"Sleep"},{"issue":"3","key":"noi230085r15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/mds.v37.3","article-title":"Rapid eye movement sleep behavior disorder: abnormal cardiac image and progressive abnormal metabolic brain pattern.","volume":"37","author":"Janzen","year":"2022","journal-title":"Mov Disord"},{"issue":"2","key":"noi230085r18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/gim.2012.107","article-title":"Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling.","volume":"15","author":"Rana","year":"2013","journal-title":"Genet Med"},{"issue":"1","key":"noi230085r19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/brain\/awaa365","article-title":"Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder.","volume":"144","author":"Arnaldi","year":"2021","journal-title":"Brain"},{"issue":"3","key":"noi230085r20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ana.v82.3","article-title":"Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder.","volume":"82","author":"Iranzo","year":"2017","journal-title":"Ann Neurol"},{"issue":"8","key":"noi230085r21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamaneurol.2017.0985","article-title":"Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort.","volume":"74","author":"Jennings","year":"2017","journal-title":"JAMA Neurol"},{"issue":"5","key":"noi230085r22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using a-synuclein seed amplification: a cross-sectional study.","volume":"22","author":"Siderowf","year":"2023","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi230085r23","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","article-title":"Propagative a-synuclein seeds as serum biomarkers for synucleinopathies.","volume":"29","author":"Okuzumi","year":"2023","journal-title":"Nat Med"},{"issue":"18","key":"noi230085r24","doi-asserted-by":"publisher","first-page":"e1944","DOI":"10.1212\/WNL.0000000000207147","article-title":"Misfolded a-synuclein assessment in the skin and CSF by RT-QuIC in isolated REM Sleep Behavior Disorder.","volume":"100","author":"Iranzo","year":"2023","journal-title":"Neurology"},{"issue":"24","key":"noi230085r25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add8910","article-title":"Monitoring a-synuclein ubiquitination dynamics reveals key endosomal effectors mediating its trafficking and degradation.","volume":"9","author":"Zenko","year":"2023","journal-title":"Sci Adv"},{"issue":"3","key":"noi230085r26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2011.01.029","article-title":"Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission.","volume":"42","author":"Alvarez-Erviti","year":"2011","journal-title":"Neurobiol Dis"},{"issue":"9","key":"noi230085r27","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","article-title":"Detection of neuron-derived pathological a-synuclein in blood.","volume":"145","author":"Kluge","year":"2022","journal-title":"Brain"},{"key":"noi230085r16","doi-asserted-by":"crossref","unstructured":"Seger? A, Ophey? A, Heitzmann? W, . Evaluation of a structured screening assessment to detect patients with isolated REM Sleep Behavior Disorder.? Mov Disord. 2023;38(6):990-999. doi:10.1002\/mds.29389","DOI":"10.1002\/mds.29389"},{"key":"noi230085r17","unstructured":"Parkinson\u2019s Progression Markers Initiative. The study that can change everything. Accessed October 18, 2023. https:\/\/www.ppmi-info.org\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2812433\/jamaneurology_yan_2023_oi_230085_1703025832.95749.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T16:01:44Z","timestamp":1704729704000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2812433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.4398","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}